Boehringer Ingelheim | Pakistan Newswire

EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®

Web Desk September 15, 2015 Comment Closed Business & Finance, Other Language

Secondary analyses evaluated ABASAGLAR® in patients previously treated with Lantus® insulin glargine

STOCKHOLM, Sept. 15, 2015 / PRNewswire — Data from secondary analyses of Phase III clinical trials showed that ABASAGLAR^® (insulin glargine), Eli Lilly and Company and Boehringer …

Read more »
Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product

Web Desk December 23, 2013 No Comment Medical/Health Care

– New Drug Application follows submission of Marketing Authorisation Application to the European Medicines Agency

INDIANAPOLIS and INGELHEIM, Germany, Dec. 20, 2013 / PRNewswire – Eli Lilly and Company and Boehringer Ingelheim today announced that the U.S. Food and Drug …

Read more »